The Large Molecule CDMO arm of Mantell Associates covers all appointments across Contract Development and Manufacturing for Biological entities, including Vaccines, Cell & Gene Therapy, Biosimilars, Monoclonal Antibodies and Recombinant Proteins.
Mantell Associates is enormously busy across this space right now with all of the work being done by our clients, against COVID-19 in particular. A few of the biggest movers and shakers in this market are listed below…
Marc Funk, Chief Executive Officer
Moved to:Recipharm
Moved from:Lonza
Sector: Large Molecule CDMO
Marc came from a legal background where he became the Head of Corporate Counsel for Merck, from there he progressed through the ranks at Lonza, holding multiple positions such as Chief Legal Counsel, CEO, and President & COO. He has now been appointed as the CEO of Recipharm, where there is certainly an exciting journey ahead for the company. Recipharm are expanding into many different areas, offering true end to end solutions across Small & Large Molecule and they have now instantly become a company to watch as they aim to become the #1 CDMO on the market.
Jayanth Sridhar, Chief Executive Officer
Moved to: Dr. Reddy's Laboratories
Moved from: Biological E. Limited
Sector: Large Molecule CDMO
Jayanth is a hugely respected figure within the Biologics space, with around 25 years’ experience including impressive stints with Biocon, Cipla Biotec, and as CTO for the enigmatic Biosimilars organisation, Alvotech. Most recently, Jayanth was Senior Vice President for Viral Vaccines at Biological E. Limited before his latest move to the globally renowned Dr. Reddy’s as CEO, Global Head of Biologics where he has oversight of the entire Biologics business unit. Using all of his experience gained within the Biotech space, Jayanth will continue to fly the flag high for Dr. Reddy’s.
Frank Ternes, Chief Business Officer
Moved to:Recipharm
Moved from:Polpharma Biologics
Sector:Large Molecule CDMO
Frank is a Pharmaceutical, Biotech and Life Sciences Global Operations, Supply Chain and B2B Sales Professional with more than 30 years industry experience. Throughout his career, Frank skilfully managed organisational change, using a unique leadership style which has inspired staff to deliver outstanding results and build consensus on company vision and direction. Due to the success that Frank has achieved everywhere he has worked, he made the perfect addition to Marc Funk’s C-Suite at Recipharm. No doubt they will already have a clear vision in place, and they stand every chance of achieving it.
Darren Head, Chief Executive Officer
Moved to: Bionova Scientific
Moved from: MaSTherCell
Sector: Large Molecule CDMO
Darren has over 26 years of biological, device and drug manufacturing experience, and recently joined Bionova Scientific as the new CEO after successful spells with MaSTherCell and Cytovance. Under his leadership, Cytovance grew their revenues over 40% per year and increased significantly in headcount. As CEO, Darren was also instrumental in the facilitation of the sale of MaSTherCell to Catalent Biologics in 2020. With Darren’s astute leadership and unquestionable track record over 30 years, Bionova Scientific are well prepared to grow and succeed in a variety of situations.
Martin Keßler, Chief Executive Officer
Moved to:Rentschler Biopharma SE
Moved from:McKinsey & Company
Sector:Large Molecule CDMO
Martin has spent the largest part of his career with McKinsey and Company where he reached Associate Partner. Needless to say, anybody who has worked for McKinsey is undoubtedly held in high esteem. PhD educated in Economics and Supply Chain; he has most recently been appointed as Chief Executive Officer at Rentschler Biopharma SE in the US, where he is leading the transformation for their business operations centred in Massachusetts. Martin has joined the leadership team of a very exciting organisation and it will be interesting to follow their journey together.
A NOTE FROM OUR CEO: Alessandro Mantell
It is with great pride and excitement that Mantell Associates have launched our first ever ‘Movers & Shakers’, which has been designed to highlight some of the biggest moves across the Life Science & Pharmaceutical Industry within the first six months of 2021.
Anyone who has followed the Mantell Associates journey so far will see the great extent of the effort and care that we have invested into making Mantell Associates not just ‘another recruitment business’ but a truly specialist, high-level headhunting organisation. We focus on Senior level appointments and consulting services, but we strive to share market intelligence and industry relevant content, and to provide exposure for individuals and businesses through the Mantell Associates Network podcast, which has already featured 21 industry leaders. In this ‘Movers & Shakers’ we look at the high level leadership moves between January and June this year, in particular across CDMO Large Molecule, CDMO Small Molecule, Life Sciences, Medical Devices & Consultancies, Market Access, HEOR. The incredible people and businesses that we highlight in this particular ‘Movers & Shakers’ are not only those who changed role but rather those who, during an incredibly difficult time, saw an opportunity to make an impact on the world and those around them.
Thank you from all of the Mantell Associates team – we hope you enjoy it!